New dual-acting treatments against tough Klebsiella pneumoniae infections
Official title: Novel Dual-Acting Therapeutics Against High-Threat K. pneumoniae
Funded at State University of New York at Buffalo · NIH-11563773 · Data updated 2026-11-12
A new funding opportunity aims to develop therapies that both fight and disarm the dangerous Klebsiella pneumoniae bacteria, especially strains that resist many drugs, to help patients with serious infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $799,743 |
| NIH project number | 1R56AI198403-01 |
| Project ID | NIH-11563773 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with or at risk for serious Klebsiella pneumoniae infections, including those with bloodstream infections or hospital-associated infections, may benefit from the research outcomes.
✕Less likely to help
Patients without infection or exposure to resistant strains may not directly benefit from this research.
What this research studies
This grant supports research aimed at creating therapies that tackle harmful Klebsiella pneumoniae by combining approaches that kill the bacteria with methods that reduce its ability to cause severe disease. Researchers will explore agents and combinations, including antibodies and bacteriophages, to overcome drug resistance and target the bacteria’s virulence factors like its capsule. The work will involve preclinical studies using models of infection to test how well these dual-acting strategies work to protect patients and reduce mortality from bloodstream and hospital-acquired infections. If successful, the findings could lead to new treatment options for people with resistant K. pneumoniae infections and help curb hospital outbreaks.
Why it matters
Potential benefit: If successful, patients could have new, effective treatment options against drug-resistant Klebsiella infections.
How similar studies have gone: Past work shows promise in targeting bacterial virulence and using combination therapies, but the dual-action approach against high-threat K. pneumoniae is relatively novel.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Chen, Liang — State University of New York at Buffalo
- Study coordinator: Chen, Liang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.